Plerixafor (Mozobil®) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 695-700

  Flomenberg, Neal ^a   Comenzo, Raymond L ^b   Badel, Karin ^c   Calandra, Gary ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

AMD3100; Autologous transplantation; Multiple myeloma; Plerixafor; Stem cell mobilization

Indexed keywords

PLERIXAFOR; CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROCYCLIC COMPOUND;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENGRAFTMENT; FEMALE; GASTROINTESTINAL DISEASE; GRAFT SURVIVAL; HEMATOPOIESIS; HUMAN; HUMAN CELL; INJECTION SITE REACTION; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPHIL; ORAL PARESTHESIA; STEM CELL MOBILIZATION; THROMBOCYTE; ADOLESCENT; AUTOTRANSPLANTATION; DRUG ANTAGONISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KINETICS; METHODOLOGY;

ADOLESCENT; ADULT; AGED; BLOOD COMPONENT REMOVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; KINETICS; MALE; MULTIPLE MYELOMA; RECEPTORS, CXCR4; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77951206198     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.12.538     Document Type: Article

References (18)

1. Katayama Y., Battista M., Kao W.M., et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124:407-421.
2. Mendez-Ferrer S., Lucas D., Battista M., Frenette P.S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008, 452:442-447.
3. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004, 103:1580-1585.
4. Hatse S., Princen K., Bridger G., De Clercq E., Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
5. Liles W.C., Broxmeyer H.E., Rodger E., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
6. DiPersio J.F., Micallef I., Stiff P.J., et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annu Meet Abstr 2007, 110:601.
7. Dipersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
8. Flomenberg N., Devine S.M., Dipersio J.F., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
9. Broxmeyer H., Orschell C., Clapp D., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
10. Larochelle A., Krouse A., Metzger M., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in non-human primates. Blood 2006, 107:3772-3778.
11. Seeger T., Veldwijk M., Topaly J., et al. The CXCR4 antagonist AMD3100 mobilizes a more primitive subset of CD34+ cells than G-CSF. 47th ASH Annual Meeting and Exposition, Atlanta, GA 2005, [poster].
12. Hess D.A., Bonde J., Craft T.P., et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007, 13:398-411.
13. Devine S.M., Vij R., Rettig M., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
14. Dispenzieri A., Moreno-Aspitia A., Suarez G.A., et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004, 104:3400-3407.
15. Gertz M.A., Lacy M.Q., Bjornsson J., Litzow M.R. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res 2000, 9:635-643.
16. Hendrix C., Collier A., Lederman M., et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004, 37:1253-1262.
17. Rettig M.P., Shannon W.D., Ritchey J., et al. Characterization of human CD34+ hematopoietic stem cells following administration of G-CSF or plerixafor. Blood (ASH Annu Meet Abstr) 2008, 112:3476.
18. Cashen A., Lopez S., Gao F., et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1253-1261.